HTB news: managing low-level viral load (LLV), new drug interactions, dolutegravir for newborns

1 July 2026. Related: News.

July news – June news – May news – All back issues

Recent HTB highlights

• New guidelines on persistent low-level viral load in people living with HIV

New guidelines on the management of persistent low-level viraemia (LLV) by an international panel of more than 100 experts and are now published in Lancet HIV. Importantly, they recognise there can be two distinct mechanisms for viral rebound: (i) ongoing replication which can be resuppressed or (ii) viral production from reservoir site which is non-suppressible.

• Important drug interactions between HIV drugs and encorafenib and dabrafenib
• Updated US paediatric HIV guidelines include dolutegravir from birth
• FDA and EMA applications to expand dolutegravir indication to newborns from birth

All reports

• June 2026
• All back issues

Subscribe to HTB by email to receive the latest news every 3-4 weeks.

Reports will also be posted to social media.

Twitter (X) – Bluesky – Facebook – Instagram